Dr Andtbacka meets with ecancertv at WCCS 2016 to discuss the use of oncolytic virotherapy (OV) in the treatment of melanoma. He discusses the OPTiM trials of T-VEC, a genetically modified herpes virus, including identifying which patients have the most durable response, and looks forward to...

Prof Lorrigan speaks with ecancertv at WCCS 2016 about the changing role of chemotherapy for metastatic melanoma. Given the emergence of alternative therapies, he considers which tumour types and patient subgroups may be more or less responsive, and how to take chemotherapy into a changing field...